Review Article

Immunotherapy in the Treatment of Metastatic Melanoma: Current Knowledge and Future Directions

Massimo Ralli,1 Andrea Botticelli,2 Irene Claudia Visconti,1 Diletta Angeletti,1 Marco Fiore,3 Paolo Marchetti,2 Alessandro Lambiase,1 Marco de Vincentiis,4 and Antonio Greco1

1Department of Sense Organs, Sapienza University of Rome, Viale del Policlinico 155-00161 Rome, Italy
2Department of Clinical and Molecular Medicine, Sapienza University of Rome, Viale del Policlinico 155-00161 Rome, Italy
3Institute of Cell Biology and Neurobiology, IBCN-CNR, Rome, Italy
4Department of Oral and Maxillofacial Sciences, Sapienza University of Rome, Viale del Policlinico 155-00161 Rome, Italy

Correspondence should be addressed to Massimo Ralli; massimo.ralli@uniroma1.it

Received 28 March 2020; Revised 24 May 2020; Accepted 8 June 2020; Published 28 June 2020

Academic Editor: Eirini Rigopoulou

Copyright © 2020 Massimo Ralli et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Melanoma is one of the most immunologic malignancies based on its higher prevalence in immune-compromised patients, evidence of brisk lymphocytic infiltrates in both primary tumors and metastases, documented recognition of melanoma antigens by tumor-infiltrating T lymphocytes and, most important, evidence that melanoma responds to immunotherapy [1–3].

Immunotherapy is one of the most efficient therapeutic strategies in melanoma because of the high immunogenicity of this tumor. The mechanisms of action of immunotherapy are focused on specific targets of the counter-regulatory mechanisms of the immune response [4–8]. However, immunotherapy is also associated with immune-related adverse events (irAEs) that represent tissue-specific dysimmune inflammatory responses [9–14].

1. Introduction

Melanoma is an immunologic malignancy characterized by higher prevalence in immune-compromised patients, evidence of brisk lymphocytic infiltrates in both primary tumors and metastases, documented recognition of melanoma antigens by tumor-infiltrating T lymphocytes and, most important, evidence that melanoma responds to immunotherapy [1–3].

Immunotherapy is one of the most efficient therapeutic strategies in melanoma because of the high immunogenicity of this tumor. The mechanisms of action of immunotherapy are focused on specific targets of the counter-regulatory mechanisms of the immune response [4–8]. However, immunotherapy is also associated with immune-related adverse events (irAEs) that represent tissue-specific dysimmune inflammatory responses [9–14].

This review paper discusses current knowledge and future directions in melanoma immunogenicity and immunotherapy.

2. Metastatic Melanoma

The incidence of cutaneous melanoma has rapidly increased in the past decades. Melanoma is the ninth most common malignancy and the second for mortality. Every year, there are nearly 100,000 new cases of melanoma in the United States, and about 9,000 patients die of this cancer [15]. Despite prevention campaigns, melanoma incidence has increased at a faster rate compared to most other cancers, especially in young Caucasian women [16].

Melanoma patients with distant metastases show a 5-year survival rate of 23%, making metastasis the leading cause of melanoma-associated deaths [17].
Several factors are involved in the pathogenesis of melanoma, including environmental, genetic, and immunological ones [18–20]. Of these, research has mainly focused on the activation of the immune system, especially for the possibility of developing specific targeted therapies [1, 2, 18, 19].

2.1. Environmental Factors. Studies have revealed that many factors may favor the development of melanoma; among them, the environment and the exposure to ultraviolet (UV) rays play an important role [21–24]. The incidence of melanoma varies by geographic location among people of the same ethnicity. Different locations can translate into differences in atmospheric absorption, latitude, altitude, cloud cover, and seasonality, thus influencing incident UV radiation [1, 2]. In 1956, Lancaster found increasing melanoma mortality rates with increasing proximity to the equator, a phenomenon he termed the “latitude gradient” [25]. Since then, similar trends of melanoma incidence have been reported around the world. In the lowest latitudes, melanoma annual incidence tends to be higher than in higher latitudes [26] (Figure 1).

Differences in altitude have also been suggested to have a role in melanoma incidence. In countries with both high- and low-latitude locations, higher altitudes have been associated with higher melanoma incidence. In fact, the UV irradiance is associated with higher altitude; furthermore, with higher altitude, there are also changes in ozone absorption, decreased cloud cover, and increased surface reflectance from snow cover which can also increase UV radiation [27].

2.2. Genetic Factors. Genetics factors may have a role in the pathogenesis of melanoma. In 2005, Uhara et al. reported an elevated detection of the BRAF mutation in patients with melanoma without chronic sun-induced damage [28, 29]. Further research showed that nearly 40–50% of cutaneous melanomas have mutations in BRAF, a gene that belongs to the family of mitogen activated protein kinase (MAPK) and codes for a serine/threonine protein kinase constituting part of RAS-RAF-MEK [30, 31]. BRAF activation induces the phosphorylation of extracellular signal-regulated kinases (ERK) that constitute the most common mutated isoforms in cancer [32]. The most common mutation is the V600E; in some cases, another mutation of BRAF named V600K has been described [33]. Some other gene mutations have been described in studies such as NRAS and KIT. Therefore, studies have revealed that there is a high mutation rate in melanoma when comparing to other common tumors [34, 35].

The recently identified high-risk variants such as BRCA1 Associated Protein 1 (BAP1), Protection of Telomeres Protein 1 (POT1), Adrenocortical Dysplasia (ACD), Telomeric Repeat-binding Factor-2 Interacting Protein (TERF2IP), and Telomerase Reverse Transcriptase (TERT) contribute to about 2% of melanoma’s missing heritability [36].

Pastorino et al. also studied Ataxia-Telangiectasia Mutated (ATM) gene to define its role as a susceptibility gene for cutaneous melanoma. The authors reported a high percentage of deleterious ATM variants in melanoma families (3.3%) [37].

Recently, Casula et al. used a panel containing the same genes (with the exception of MITF) in a sample of Italian patients with cutaneous malignant melanoma and found a lower pathogenic variant rate based on the American College of Medical Genetics on Genomics variant classification (3%); in addition, a low level of heterogeneity in driver somatic mutations in subjects with numerous melanomas was reported [38].

2.3. Immunological Factors. The high immunogenicity of melanoma is the base of the relationship between this cancer and the immune system [2, 5, 15, 18–20, 39]. The main characteristic of the immune system is to recognize the antigen as self or nonself. It is clear that the progression of melanoma is based on a lack of activation of the immune system and the ability of the tumor of doing the so-called “immune escape”. This is further supported by the evidence that some melanoma patients present with metastatic disease without an evident primary lesion; these cases are also known as “melanoma of unknown primary” and are based on immunoediting mechanisms [34, 40] (Figure 2).

The characteristics of an efficient immune system include a fast, nonspecific phase which activates the innate response and a second specific adaptive response [15, 41]. The response starts with the release of tumor antigens presented by antigen-presenting cells (APC) to T cells in the lymph nodes. APC are primarily dendritic cells (DC). Subsequently, T cells including CD8+ cytotoxic lymphocytes (CTL) reach the tumor where they recognize and kill malignant cells and contribute realizing more cancer antigens [32, 42]. Tumor-associated antigens, which are recognized by autologous antibodies and T cells, have been identified and classified in melanoma [16]. They can be characterized as differentiation antigens such as glycoprotein 100 (gp100), tyrosinase, and Melan-A.

A crucial role in the activation of the immune system is played by the costimulatory molecules. These molecules work to activate T cell response, amplify signals, or counteract T cell complex signals [43]. They represent one of the targets of immunotherapy in the treatment of metastatic melanoma [43].

The immune system is able to control the disease only in the initial phases, when the tumor is still in an early phase and defence mechanisms are still efficient; furthermore, the cancer causes the exhaustion of the immune system through a continuous antigenic stimulation. The exhaustion of the immune system and the immune escape allow melanoma to grow and become metastatic [15, 16, 18, 19, 39]. Briefly, melanoma cells can evade immune detection through a reduction of the expression of immunogenic tumor antigens, a reduction of the histocompatibility complex class I (MHC I), the alteration of the antigen process, the recruitment of the immunosuppressive cells such as T reg and suppressor cells derived from myeloid cells, and the reduction of immunosuppressive molecules such as TGFB, Vascular-Endothelial Growth Factor (VEGF), adenosine, or Indoleamine 2,3-dioxygenase enzyme (IDO) [32, 44–46].
3. Immunotherapy for Metastatic Melanoma

Immunotherapy is now considered a promising new approach for the treatment of metastatic melanoma [47–49], even if its role is a relatively late discovery for this malignancy. One of the main characteristics of immunotherapy is the resistance to radiation therapy and cytotoxic chemotherapy. In the past, the key drug for melanoma was Dacarbazine, with an overall response rate (ORR) of 10-20%; however, there were no differences between Dacarbazine monotherapy and a combined chemotherapy. No better results have been reported for radiotherapy. Despite the poor clinical results, these approaches have been the main drivers in melanoma treatment for decades [50–52].

The new immunotherapy is the treatment that has been most extensively studied in metastatic melanoma [53]. Immunotherapy can be divided into four main groups [17]. The first include biological medications such as cytokines,
interferons, and granulocyte-monocyte colony-stimulating factors [54]. The second is the vaccination strategy based on peptide, on the whole protein, on virus, on DNA, or on DC [55]. The third group is based on adoptive cell therapy, which consists in the use of the so-called lymphokine-activated killer (LAK) cells, tumor-infiltrating lymphocytes (TIL), and other specific lymphocytes [56, 57]. The fourth group consists of immune checkpoint inhibitors; in the last few years, the immunologic origin of this malignancy has led to the discovery of antibodies directed to specific targets such as antiprogrammed cell death 1 (PD-1) and anticytotoxic T-lymphocyte-associated protein 4 (CTLA-4) [4, 5, 58]. These blockers have drastically increased and elongated the overall survival (OS) of metastatic melanoma [28].

3.1. Biological Immunotherapy. The biological immunotherapy was the first used in the treatment of metastatic melanoma to replace or complete the action of chemotherapy. The most common medications used in biological immunotherapy are high doses of interleukin 2 (IL-2) and interferons [59–61]. Biological immunotherapy is often used in combination with stereotactic radiotherapy [53, 62], vaccines or anti-CTLA-4 antibodies, although such combined approaches have not been validated yet and only single-agent use is approved except of clinical trials.

3.2. Vaccination Strategies for Melanoma. Several strategies are currently being explored to find an effective vaccine-based therapy for melanoma, including those that have the capability to target melanoma cells directly, DC-based vaccines, peptide-based vaccines, and vector-based vaccines [49, 63]. Vaccines targeting melanoma cells are an active, specific immunotherapy based on the use of patients' own or donors' melanoma cells from resected tumors [64].

DCs are antigen-presenting cells with an elevate capacity of inducing T cell immunity through the activation of cytotoxic T cell response and proinflammatory cytokine response. DC-based vaccines have limited efficacy since tumors tend to reside in immunosuppressive microenvironments [65–67]. Viruses can infect cells and stimulate the immune response. Vaccine viruses act as oncolytic agents by activating the immune system against tumors through the production of cytokines and other immunomodulatory molecules [68]. Several oncolytic viruses have been developed based on viruses such as adenovirus, herpes simplex virus (HSV), reovirus, retrovirus, vesicular stomatitis virus, and measles virus [69]. It has been reported that replication-competent HSV in which the neurovirulence is inactivated leads to cell death in human melanoma cell lines in vitro and selectively replicates in melanoma tissue in nude mice [70]. These viruses have also been shown to be safe in phase I clinical trials by intratumoral injection in glioma and melanoma patients [70]. The main advantage of the oncolytic virus therapy is that virus replication not only directly acts on tumor cells but also disseminates the therapeutic agent further through the tumor tissue. The aim of ongoing research is to increase the tumor-selective replicative capability of the virus and its immune stimulating ability to provide a multi-modal cancer therapy.

DNA-based vaccines have been shown to be safe and immunogenic in clinical trials; however, to date, they have not shown satisfactory effectiveness [71, 72].

3.3. Adoptive Cell Therapy. Good results came from the use of adoptive cell therapy (ACT), although this is still at an experimental level and requires further validation before being considered a safe and efficacious strategy. ACT is the collection of lymphocytes from the blood or tumor of the patient and their selection, expansion, and activation in vitro. The processed lymphocytes are then infused to the patient to induce an immune anticancer response [39, 53, 73, 74]. A schematic of adoptive immunotherapy is shown in Figure 3.

The cells that are most commonly used for ACT are peripheral blood lymphocytes or TILs and LAKs [39, 74]. A novel approach of ACT is the infusion of isolated and expanded autologous CD4+ T cells previously activated using the melanoma-associated antigen (NY-ESO-1) [75]. These therapies require the development of a specific therapeutic plan with a "custom made drug" for each patient; furthermore, they require weeks of cell culture, skilled personnel, and patient preparation.

3.4. Immune Checkpoint Blockade. The progression of a correct immune response is characterized by some immunological checkpoints that prevent unwanted and harmful self-directed activities that lead to autoimmunity [76, 77]. Therapies developed to overcome these mechanisms by blocking the inhibitory checkpoints allow generating antitumor activity alone or in synergism with other therapies. In melanoma, these therapies target molecules that are pathologically overexpressed in melanoma such as PD-1 or CTLA-4 [78–82].

CTLA-4, which is a member of the CD28 superfamily, is induced after CD28 binding and activation. B7-1 and B7-2 are the specific ligand of CTLA-4. The interactions between CTLA-4 and activated T cells lead to another downregulator signal, blocking IL-2 transcription and so the progression through the cell cycle [4, 83–86]. The most important molecule that blocks CTLA-4 is Ipilimumab [87]; studies have shown promising results with this molecule and durability of the response, even when the treatment was discontinued [88]. Ipilimumab, a human monoclonal IgG1 antibody against CTLA-4 given at a dose of 3 mg/kg every 3 weeks for four times, represents the first FDA-approved immune checkpoint inhibitor in metastatic melanoma [87].

PD-1 is a cell-surface molecule with inhibitory properties expressed by activated T and B cells and natural killer lymphocytes that downregulates the effector function [28, 53, 89]. Studies have proven the increase of PD-1 in melanoma, which means a strong downregulation of activated T cells that helps the maintenance of tumor cells [32, 90, 91]. Nivolumab and Pembrolizumab target the interaction between PD-1 and its ligands PDL-1 and PDL-2; in melanoma, PDL-1 expression is enhanced by the presence of interferon-gamma-secreting lymphocytes from the microenvironment. Many trials have studied the efficacy of
Nivolumab and Pembrolizumab in melanoma especially in comparison with Ipilimumab [92–96] and have shown a significant clinical efficacy. More recently, Gambichler et al. focused on the importance of the assessment of circulating PD-1+ regulatory T cells to predict the treatment response to PD-1 blockers such as Nivolumab and Pembrolizumab. The authors showed that circulating PD-1+ Tregs rapidly decline after the initiation of treatment with PD-1 blocking antibodies with a reduced risk for disease progression and metastatic disease [97].

Food and Drug Administration (FDA) approved Nivolumab as a single agent for patients with BRAF V600 wild-type unresectable or metastatic melanoma and in combination with Ipilimumab for patients with melanoma with lymph node involvement or metastatic disease who have undergone complete resection. Similarly, Pembrolizumab has been approved for patients with unresectable or metastatic melanoma [98–101].

One of the new frontiers of immune checkpoint inhibition is the possibility to achieve long-term survival thanks to the memory of the immune system. In fact, immunotherapy tends to turn the tumor into a chronic disease in a percentage close to 20%; in a recent meta-analysis on nearly 5,000 patients with advanced melanoma treated with Ipilimumab, the authors showed that nearly 20% of the patients were alive at 10 years [102].

Another novel issue is the evaluation of response and the identification of the endpoints. Indeed, Ipilimumab was the first drug to show improvement in OS for over 30 years, despite its impact on the ORR and the fact that progression-free survival (PFS) did not match the survival benefits achieved [4, 17, 39, 98]. This effect of OS was also shown with Nivolumab in kidney cancer [103].

This effect could depend on one side on the stimulation of the immune system and its slower activity and on the other on the immune checkpoint inhibitor treatment, in which it was firstly observed the phenomenon of pseudoprogression [104]. Pseudoprogression is characterized by an increase in the number of cells of the immune system, rather than of tumor cells, determining the appearance of the nodal progression that can be followed by the regression of the tumor; the rate of pseudoprogression is about 10-13% [105].

3.5. Combination Immunotherapy. Studies have revealed that the potency of cancer therapies is in the combination of drugs. Despite the success of immune checkpoint inhibitors, only a few patients have reached durable clinical responses with monotherapy. In fact, the most successful result of these medications is the possibility of using them in combination with other immune checkpoint blockers, chemotherapy, radiotherapy, or targeted molecular therapy [32, 58, 106, 107].

Rosner et al. recently described the success of combined Ipilimumab and Nivolumab and the peripheral blood clinical laboratory variables associated with the outcome in melanoma [108]. Moreover, in 2015, Postow et al. revealed an ORR of 61% in patients treated with the association of Nivolumab and Ipilimumab in comparison to patients treated only with placebo [94]. Another study compared patient with unresectable stage III or IV melanoma treated with Nivolumab alone, Ipilimumab alone, and Nivolumab plus Ipilimumab shows that median PFS was 11.5 months in the combination group, 6.9 in the Nivolumab group, and
only 2.9 in the Iplimumab group. These results show both the efficacy of comparison therapy and the good impact of Nivolumab in the treatment of metastatic melanoma [109].

Another combination therapy that had interesting outcomes is represented by the Indoleamine 2,3-dioxygenase (IDO) inhibitors and the PD-1 blockers. IDO is a cytosolic enzyme expressed in various tissues with the ability to catalyze tryptophan to kynurenine resulting in tryptophan depletion and suppression of T cell functions. The presence of IDO in melanoma has negative prognostic implications as shown in peritumoral endothelium cells or lymph nodes. Surprisingly, the combination of IDO inhibitors and anti PD-1 antibodies has failed to demonstrate an increase in OS in patients treated with combination therapy compared to single-agent treatment [110–113].

In patients with BRAF mutation, the ideal sequence of treatment or the choice of sequence of combination is still an open issue [4, 31, 98]. The results of two large ongoing studies are awaited. The SECOMBIT is a randomized comparative three-arm study, which explores combined immunotherapy (Iplimumab plus Nivolumab) followed by targeted combination therapy (Encorafenib plus Binimetinib) or vice versa in patients with metastatic mutated melanoma with BRAF; its design includes an 8-week induction with the targeted combination therapy, followed by combination immunotherapy, and subsequently by the target combo to progression [114, 115]. The ECOG 6134 study is a randomized phase III trial comparing Iplimumab plus Nivolumab followed by Dabrafenib plus Trametinib versus Dabrafenib plus Trametinib followed by Iplimumab and Nivolumab in patients with advanced melanoma.

3.6. Future Directions. Actually, the first-line therapeutic approach for advanced melanoma consists in immunotherapy with anti-PD1 antibodies or targeted therapy with BRAF and MEK inhibitors. Evidence is accumulating on the use of new therapeutic agents for immunomodulatory treatment such as LAG3, TIM3, OX-40, CD137, IDO, and GITR. Researches concerning fully available treatment options as such as LAG3, TIM3, OX-40, CD137, IDO, and GITR. New therapeutic agents for immunomodulatory treatment and include developing new drugs are ongoing [116, 117]; however, the optimal first-line treatment for advanced melanoma patients is still unknown [39].

4. Immune-Related Adverse Events to Immunotherapy

Although immunotherapy is a targeted therapy and therefore it is better tolerated compared to common chemotherapy, it has been associated with the emergence of a new panel of dysimmune toxicities called irAEs [9, 118–120].

To date, different irAEs following immune checkpoint inhibitor therapy have been reported [121, 122]. They include dermatologic [123, 124], gastrointestinal [125], pulmonary [126], endocrine [127–129], renal [130], ophthalmologic [131], rheumatic [132], cardiovascular [133], and hematologic [134] adverse events, although they can potentially affect any tissue [122].

Dermatologic toxicities are the most common irAEs and affect up to 50% of treated patients. They include rash, pruritus, dermatitis, vitiligo and bullous dermatitis [123, 124]. Interestingly, the development of vitiligo is associated with an improved prognosis both in early and advanced disease [34]. In particular, vitiligo development in patients with stage III or IV melanoma was associated with a regression of the tumor and prolonged survival [124, 135].

Gastrointestinal irAEs include colitis, hepatitis, and pancreatitis [125]. The most common is colitis, which usually presents as diarrhea and can affect up to 40% of patients. Hepatitis may present in up to 30% of cases and presents with an increase of transaminases. Pancreatitis, which is less common, presents with increased amylase/lipase and typical clinical symptoms [136–138].

The development of thyroid disorders such as hyperthyroidism and hypothyroidism has been reported in 6%-20% of patients treated with checkpoint inhibitors [139]. The incidence of these conditions varied among patients who received single or a combination of immunotherapeutic agents [139]; studies have shown that patients treated with a combination regimen were more likely to develop thyroid alterations although their pathogenesis is still unknown [127–129].

Pulmonary irAEs include pneumonitis and sarcoidosis [140]. In case of development of pneumonitis during treatment, immunotherapy should be discontinued [126]. Sarcoidosis is a rare pulmonary toxicity in patients receiving immune checkpoint inhibitors [140, 141].

Musculoskeletal and rheumatologic adverse events occur in 2%-12% of patients and may present as inflammatory arthritis, myalgias, myositis, and polymyalgia-like syndromes [132].

Renal adverse events have been described in 2%-5% of patients and usually occur within the first 3–10 months of anti-PD1 therapy and within 2–3 months of anti-CTLA-4 therapy [130]. Renal toxicity can present with oliguria, hematuria, and peripheral edema.

Ophthalmic irAEs may present with vision alteration, optic nerve swelling, uveitis, episcleritis, and blepharitis; they are rare and have an incidence < 1% in patients receiving immunotherapy [131].

Neurologic irAEs include myasthenia gravis, peripheral neuropathy, Guillain–Barre syndrome, encephalitis, aseptic meningitis, hypophysitis, and transverse myelitis [142]. Similar to ocular adverse events, these irAEs are rare and affect less than 1% of patients [143, 144].

irAEs affecting the cardiovascular system have an incidence < 1%, usually occur within the first month of treatment and include myocarditis, arrhythmias, pericarditis, and impaired ventricular function [133, 145].

Hematologic irAEs include autoimmune hemolytic anemia, hemolytic uremic syndrome, lymphopenia, thrombocytopenia, plastic anemia, and acquired hemophilia. These adverse events are rare [134, 146].

5. Biomarkers

Despite the promising results, only 20-40% of melanoma patients present long-term benefits, while the remaining 80% develop primary or secondary resistance to immune-
checkpoints inhibitors [8, 90, 107]. These patients are characterized by a very short PFS and OS. To date, no reliable factors have been identified to predict response to immune checkpoint inhibitors.

PD-L1 is the biomarker that has been most extensively studied thanks to its characteristic of being expressed on both tumor and inflammatory cells. However, the determination of PD-L1 has several issues, such as the extremely high dynamic marker properties, the different immunohistochemical antibody and assay in clinical practice resulting in different cut-off points, and the evidence that biopsies may not be representative of the entire tumor [82, 92, 93]. Even if still controversial, the association of high level of PD-L1 expression on tumor cells and increased response to anti-PD-1/PD-L1 treatment has been demonstrated by several studies [147].

Tumor mutational load is a promising biomarker that has been shown to correlate with better anti-PD-1 response for both Pembrolizumab and Nivolumab and combination of Nivolumab and Ipilimumab in patients affected by lung cancer but not in melanoma patients [148]. Furthermore, promising results come from the study of T cell repertoire [147], major histocompatibility complex (MHC) status [149], Interferon Y signature [150], and immune infiltrates [151].

The microbiota composition seems to influence the response and toxicity to immunotherapy. In germ-free mice model and antibiotic-treated mice, the response to CTLA-4 is reduced and the Bifidobacterium increases antitumor immunity and facilitates anti-PD-L1 activity [152–154]. In two different cohorts of melanoma patients treated with anti-CTLA-4, a significant association was observed between commensal microbiome composition and toxicity [155, 156].

Recently, it was demonstrated that Faecalibacterium is associated with better response to immune checkpoint inhibitors in melanoma patients treated with anti PD-1 [157].

New frontiers are represented on one side by the faecal transplantation as recently demonstrated in two case reports to treat colitis induced by immunotherapy [158], and on the other side by the study of metabolic profiles of microbiota and of the functional read out of host-microbiota interaction [159].

In any case, the tumor and patient immunological status, nutritional status, and the microbiome profile should be considered to better target the new immunotherapy strategy [160].

6. Conclusions

Metastatic melanoma is a malignancy with a poor prognosis. The introduction of immunotherapy, alone or in combination with chemotherapy, radiotherapy, or targeted molecular therapy, has significantly changed the approach to this tumor. Nivolumab, Ipilimumab, and Pembrolizumab are the drugs that are mainly used in the clinical practice; unfortunately, immunotherapy has a specific toxicity characterized by several rAEs. Future directions in the treatment of metastatic melanoma include immunotherapy with anti-PD1 antibodies or targeted therapy with BRAF and MEK inhibitors. Evidence is accumulating on the use of new therapeutic agents for immunomodulatory treatment; however, to date, the optimal first-line treatment for advanced melanoma patients is still unknown.

Conflicts of Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References

[1] S. Carr, C. Smith, and J. Wernberg, “Epidemiology and risk factors of melanoma,” The Surgical Clinics of North America, vol. 100, no. 1, pp. 1–12, 2020.
[2] C. H. O’Neill and C. R. Scoggins, “Melanoma,” Journal of Surgical Oncology, vol. 120, no. 5, pp. 873–881, 2019.
[3] N. Iglesias-Pena, S. Paradela, A. Tejera-Vaquero, A. Boada, and E. Fonseca, “Cutaneous melanoma in the elderly: review of a growing problem,” Actas Dermo-Sifiliográficas, vol. 110, no. 6, pp. 434–447, 2019.
[4] N. A. Babacan and Z. Eroglu, “Treatment options for advanced melanoma after anti-PD-1 therapy,” Current Oncology Reports, vol. 22, no. 4, p. 38, 2020.
[5] J. Haansen, M. S. Ernstoff, Y. Wang et al., “Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention strategy,” Annals of Oncology, vol. 31, no. 6, pp. 724–744, 2020.
[6] O. Hamid, R. Ismail, and I. Puzanov, “Intratumor immunotherapy—update 2019,” The Oncologist, vol. 25, no. 3, pp. e423–e438, 2020.
[7] M. Kremenovic, M. Schenk, and D. J. Lee, “Clinical and molecular insights into BCG immunotherapy for melanoma,” Journal of Internal Medicine, pp. 1–16, 2020.
[8] C. G. Twitty, L. A. Huppert, and A. I. Daud, “Prognostic biomarkers for melanoma immunotherapy,” Current Oncology Reports, vol. 22, no. 3, p. 25, 2020.
[9] M. Ellithi, R. Elnair, G. V. Chang, and M. A. Abdallah, “Toxicities of immune checkpoint inhibitors: Its-ending adverse reactions and more,” Cureus, vol. 12, no. 2, article e6935, 2020.
[10] P. Urwyler, I. Earnshaw, M. Bermudez et al., “Mechanisms of checkpoint inhibition-induced adverse events,” Clinical & Experimental Immunology, vol. 200, no. 2, pp. 141–154, 2020.
[11] L. Spain and R. Wong, “The neurotrophic effects of immune checkpoint inhibitor therapy for melanoma,” Melanoma Management, vol. 6, no. 2, article MMT16, 2019.
[12] H. Hong, Q. Wang, J. Li, H. Liu, X. Meng, and H. Zhang, “Aging, cancer and immunity,” Journal of Cancer, vol. 10, no. 13, pp. 3021–3027, 2019.
[13] F. S. Mennini, C. Bini, A. Marcellusi, and M. Del Vecchio, “Cost estimate of immune-related adverse reactions associated with innovative treatments of metastatic melanoma,” Clinical Drug Investigation, vol. 38, no. 10, pp. 967–976, 2018.
[14] L. C. Cappelli, A. A. Shah, and C. O. Bingham 3rd., “Immune-Related Adverse Effects of Cancer Immunotherapy—Implications for Rheumatology,” Rheumatic Diseases Clinics of North America, vol. 43, no. 1, pp. 65–78, 2017.
[15] A. Passarelli, F. Mannavola, L. S. Stucci, M. Tucci, and F. Silvestris, “Immune system and melanoma biology: a
balance between immunosurveillance and immune escape,” *Oncotarget*, vol. 8, no. 62, pp. 106132–106142, 2017.

[16] M. Maio, “Melanoma as a model tumor for immuno-oncology,” *Annals of Oncology*, vol. 23, Supplement 8, pp. viii10–viii14, 2012.

[17] L. Bomar, A. Senithilnathan, and C. Ahn, “Systemic therapies for advanced melanoma,” *Dermatologic Clinics*, vol. 37, no. 4, pp. 409–423, 2019.

[18] I. G. Motofei, “Malignant melanoma: autoimmunity and supracellular messaging as new therapeutic approaches,” *Current Treatment Options in Oncology*, vol. 20, no. 6, p. 45, 2019.

[19] I. G. Motofei, “Melanoma and autoimmunity: spontaneous regressions as a possible model for new therapeutic approaches,” *Melanoma Research*, vol. 29, no. 3, pp. 231–236, 2019.

[20] E. H. Byrne and D. E. Fisher, “Immune and molecular correlates in melanoma treated with immune checkpoint blockade,” *Cancer*, vol. 123, no. S1, pp. 2143–2153, 2017.

[21] M. Rastrelli, S. Tropea, C. R. Rossi, and M. Alaiabac, “Melanoma: epidemiology, risk factors, pathogenesis, diagnosis and classification,” *In Vivo*, vol. 28, no. 6, pp. 1005–1011, 2014.

[22] S. Gandini, P. Autier, and M. Boniol, “Reviews on sun exposure and artificial light and melanoma,” *Progress in Biophysics and Molecular Biology*, vol. 107, no. 3, pp. 362–366, 2011.

[23] F. Vosmik, “Malignant melanoma of the skin. Epidemiology, risk factors, clinical diagnosis,” *Casopis Lékařů Českých*, vol. 135, no. 13, pp. 405–408, 1996.

[24] F. J. Lejeune, “Epidemiology and etiology of malignant melanoma,” *Biomedicine & Pharmacotherapy*, vol. 40, no. 3, pp. 91–99, 1986.

[25] H. O. Lancaster, “Some geographical aspects of the mortality from melanoma in Europeans,” *The Medical Journal of Australia*, vol. 43, no. 26, pp. 1082–1087, 1956.

[26] N. H. Matthews, W. Q. Li, A. A. Qureshi, M. A. Weinstock, and E. Cho, “Epidemiology of melanoma,” in *Cutaneous Melanoma: Etiology and Therapy*, W. H. Ward and J. M. Farma, Eds., Codon Publications, Brisbane (AU), 2017.

[27] F. Dimitriou, R. Krattinger, E. Rameyте et al., “The world of melanoma: epidemiologic, genetic, and anatomic differences of melanoma across the globe,” *Current Oncology Reports*, vol. 20, no. 11, p. 87, 2018.

[28] H. Uhara, “Recent advances in therapeutic strategies for unresectable or metastatic melanoma and real-world data in Japan,” *International Journal of Clinical Oncology*, vol. 24, no. 12, pp. 1508–1514, 2019.

[29] J. A. Curtin, J. Fridlyand, T. Kageshita et al., “Distinct sets of genetic alterations in melanoma,” *The New England Journal of Medicine*, vol. 353, no. 20, pp. 2135–2147, 2005.

[30] X. L. Mei, F. L. Wei, L. L. Jia, and Y. Z. Ji, “An alternative pathway for cellular protection in BRAF inhibitor resistance in aggressive melanoma type skin cancer,” *Chemico-Biological Interactions*, vol. 323, article 109061, 2020.

[31] A. Sevilla, M. C. Morales, P. A. Ezkurra et al., “BRAF V600E mutational load as a prognosis biomarker in malignant melanoma,” *PLoS One*, vol. 15, no. 3, article e0230136, 2020.

[32] H. Sadozai, T. Gruber, R. E. Hunger, and M. Schenk, “Recent successes and future directions in immunotherapy of cutaneous melanoma,” *Frontiers in Immunology*, vol. 8, article 1617, 2017.

[33] B. Y. Reddy, D. M. Miller, and H. Tsao, “Somatic driver mutations in melanoma,” *Cancer*, vol. 123, no. S1, pp. 2104–2117, 2017.

[34] D. E. Gyorki, M. Callahan, J. D. Wolchok, and C. E. Ariyan, “The delicate balance of melanoma immunotherapy,” *Clinical & Translational Immunology*, vol. 2, no. 8, article e5, 2013.

[35] G. J. Elder, P. Hersey, and P. Branley, “Remission of transplanted melanoma–clinical course and tumour cell characterisation,” *Clinical Transplantation*, vol. 11, no. 6, pp. 565–568, 1997.

[36] T. P. Potjér, S. Bollen, A. Grimbergen et al., “Multigene panel sequencing of established and candidate melanoma susceptibility genes in a large cohort of Dutch non-CDKN2A/CDK4 melanoma families,” *International Journal of Cancer*, vol. 144, no. 10, pp. 2453–2464, 2019.

[37] L. Pastorino, V. Andreotti, B. Dalmasso et al., “Insights into genetic susceptibility to melanoma by gene panel testing: potential pathogenic variants in ACD, ATM, BAP1, and POT1,” *Cancers*, vol. 12, no. 4, pp. 1007, 2020.

[38] M. Casula, P. Paligiannis, F. Ayala et al., “Germline and somatic mutations in patients with multiple primary melanomas: a next generation sequencing study,” *BMC Cancer*, vol. 19, no. 1, p. 772, 2019.

[39] I. Lugowska, P. Tetercyz, and P. Rutkowski, “Immunotherapy of melanoma,” *Współczesna Onkologia*, vol. 22, no. 1A, pp. 61–67, 2018.

[40] J. F. Scott and M. R. Gerstenblith, “Melanoma of unknown primary,” in *Noncutaneous Melanoma*, J. F. Scott and M. R. Gerstenblith, Eds., Codon Publications, Brisbane (AU), 2018.

[41] I. J. Miller and M. Sadelain, “The journey from discoveries in fundamental immunology to cancer immunotherapy,” *Cancer Cell*, vol. 27, no. 4, pp. 439–449, 2015.

[42] D. S. Chen and I. Mellman, “Oncoimmunity meets immunology: the cancer-immunity cycle,” *Immunity*, vol. 39, no. 1, pp. 1–10, 2013.

[43] E. I. Buchbinder and D. F. McDermott, “Cytotoxic T-lymphocyte antigen-4 blockade in melanoma,” *Clinical Therapeutics*, vol. 37, no. 4, pp. 755–763, 2015.

[44] I. Mellman, G. Coukos, and G. Dranoff, “Cancer immunotherapy comes of age,” *Nature*, vol. 480, no. 7378, pp. 480–489, 2011.

[45] M. W. Teng, J. Galon, W. H. Fridman, and M. J. Smyth, “From mice to humans: developments in cancer immunoeediting,” *The Journal of Clinical Investigation*, vol. 125, no. 9, pp. 3338–3346, 2015.

[46] D. Mittal, M. M. Gubin, R. D. Schreiber, and M. J. Smyth, “New insights into cancer immunoeediting and its three component phases—elimination, equilibrium and escape,” *Current Opinion in Immunology*, vol. 27, pp. 16–25, 2014.

[47] D. N. Khalil, E. L. Smith, R. J. Brentjens, and J. D. Wolchok, “The future of cancer treatment: immunomodulation, CARs and combination immunotherapy,” *Nature Reviews. Clinical Oncology*, vol. 13, no. 6, p. 394, 2016.

[48] J. Cousin-Frankel, “Cancer immunotherapy,” *Science*, vol. 342, no. 6165, pp. 1432–1433, 2013.

[49] C. J. Melief, T. van Hall, R. Arens, F. Ossendorp, and S. H. van der Burg, “Therapeutic cancer vaccines,” *The Journal of Clinical Investigation*, vol. 125, no. 9, pp. 3401–3412, 2015.

[50] K. B. Tran, C. M. Buchanan, and P. R. Shepherd, “Evolution of molecular targets in melanoma treatment,” *Current Pharmaceutical Design*, vol. 26, no. 4, pp. 396–414, 2020.
A. Sukari, N. Abdallah, and M. Nagasaka, "Chemotherapy for melanoma," Cancer Treatment and Research, vol. 167, pp. 209–229, 2016.

J. B. Haanen, "Immunotherapy of melanoma," EJC Supplements, vol. 11, no. 2, pp. 97–105, 2013.

D. Choubey, "Type I interferon (IFN)–inducible Absent in Melanoma 2 proteins in neuroinflammation: implications for Alzheimer’s disease," Journal of Neuroinflammation, vol. 16, no. 1, article 236, 2019.

B. J. Coventry, "Therapeutic vaccination immunomodulation: forming the basis of all cancer immunotherapy," Therapeutic Advances in Vaccines and Immunotherapy, vol. 7, 2019.

A. Sukari, N. Abdallah, and M. Nagasaka, "Unleash the power of the mighty T cells–basis of adoptive cellular therapy," Critical Reviews in Oncology/Hematology, vol. 136, pp. 1–12, 2019.

C. Chen and F. H. Gao, "Th17 cells paradoxical roles in melanoma and potential application in immunotherapy," Frontiers in Immunology, vol. 10, p. 187, 2019.

A. Sindoni, F. Minutoli, G. Ascenti, and S. Pergolizzi, "Combination of immune checkpoint inhibitors and radiotherapy: review of the literature," Critical Reviews in Oncology/Hematology, vol. 113, pp. 63–70, 2017.

A. Livingstone, A. Agarwal, M. R. Stockler, A. M. Menzies, K. Howard, and R. L. Morton, "Preferences for immunotherapy in melanoma: a systematic review," Annals of Surgical Oncology, vol. 27, no. 2, pp. 571–584, 2020.

M. Sanlorenzo, I. Vujic, F. Carnevale-Schiana et al., "Role of interferon in melanoma: old hopes and new perspectives," Expert Opinion on Biological Therapy, vol. 17, no. 4, pp. 475–483, 2017.

I. Rafique, J. M. Kirkwood, and A. A. Tarhini, "Immune Checkpoint Blockade and Interferon-α in Melanoma," Seminars in Oncology, vol. 42, no. 3, pp. 436–447, 2015.

S. K. Seung, B. D. Curti, M. Crittenden et al., "Phase 1 study of stereotactic body radiotherapy and interleukin-2—tumor and immunological responses," Science Translational Medicine, vol. 4, no. 137, article 137ra74, 2012.

E. Maverakis, L. A. Cornelius, G. M. Bowen et al., "Metastatic melanoma - a review of current and future treatment options," Acta Dermato-Venereologica, vol. 95, no. 5, pp. 516–524, 2015.

P. A. Ott, Z. Hu, D. B. Keskin et al., "An immunogenic personal neoantigen vaccine for patients with melanoma," Nature, vol. 547, no. 7662, pp. 217–221, 2017.

W. W. van Willigen, M. Bloemendal, W. R. Gerritsen, G. Schreiber, L. J. M. de Vries, and K. F. Bol, "Dendritic cell cancer therapy: vaccinating the right patient at the right time," Frontiers in Immunology, vol. 9, article 2265, 2018.

A. Javed, S. Sato, and T. Sato, "Autologous melanoma cell vaccine using monocyte-derived dendritic cells (NBS20/eltrapuldec-T)," Future Oncology, vol. 12, no. 6, pp. 751–762, 2016.

B. M. Carreno, V. Magrini, M. Becker-Hapak et al., "A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells," Science, vol. 348, no. 6236, pp. 803–808, 2015.

J. Kimpel, C. Urbiola, I. Koske et al., "The oncolytic virus VSV-GP is effective against malignant melanoma," Viruses, vol. 10, no. 3, p. 108, 2018.

B. L. Liu, M. Robinson, Z. Q. Han et al., "ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties," Gene Therapy, vol. 10, no. 4, pp. 292–303, 2003.

R. M. MacKie, B. Stewart, and S. M. Brown, "Intralesional injection of herpes simplex virus 1716 in metastatic melanoma," The Lancet, vol. 357, pp. 9255, pp. 525–526, 2001.

P. Mancuso, R. Tricarico, V. Bhattacharjee et al., "Thymine DNA glycosylase as a novel target for melanoma," Oncogene, vol. 38, no. 19, pp. 3710–3728, 2019.

L. Sarbu, B. E. Kitchell, and P. J. Bergman, "Safety of administering the canine melanoma DNA vaccine (Oncept) to cats with malignant melanoma – a retrospective study," Journal of Feline Medicine and Surgery, vol. 19, no. 2, pp. 224–230, 2016.

N. Halama, I. Zoernig, and D. Jaeger, "Advanced malignant melanoma: immunologic and multimodal therapeutic strategies," Journal of Oncology, vol. 2010, Article ID 689893, 8 pages, 2010.

S. A. Rosenberg, N. P. Restifo, J. C. Yang, R. A. Morgan, and M. E. Dudley, "Adaptive cell transfer: a clinical path to effective cancer immunotherapy," Nature Reviews. Cancer, vol. 8, no. 4, pp. 299–308, 2008.

N. N. Hunder, H. Wallen, J. Cao et al., "Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1," The New England Journal of Medicine, vol. 358, no. 25, pp. 2698–2703, 2008.

Y. van Holstein, E. Kapiteijn, E. Bastiaannet, F. van den Bos, J. Portielje, and N. A. de Glas, "Efficacy and adverse events of immunotherapy with checkpoint inhibitors in older patients with cancer," Drugs & Aging, vol. 36, no. 10, pp. 927–938, 2019.

E. Hui, "Immune checkpoint inhibitors," The Journal of Cell Biology, vol. 218, no. 3, pp. 740–741, 2019.

H. Shi, J. Lan, and J. Yang, "Mechanisms of resistance to checkpoint blockade therapy," Advances in Experimental Medicine and Biology, vol. 1248, pp. 83–117, 2020.

C. Robert, "Is earlier better for melanoma checkpoint blockade?", Nature Medicine, vol. 24, no. 11, pp. 1645–1648, 2018.

R. N. Amaria, S. M. Reddy, H. A. Tawbi et al., "Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma," Nature Medicine, vol. 24, no. 11, pp. 1649–1654, 2018.

L. Spain and J. Larkin, "Combination immune checkpoint blockade with ipilimumab and nivolumab in the management of advanced melanoma," Expert Opinion on Biological Therapy, vol. 16, no. 3, pp. 389–396, 2016.

K. M. Mahoney, G. J. Freeman, and D. F. McDermott, "The next immune-checkpoint inhibitors: PD-1/PD-L1 blockade in melanoma," Clinical Therapeutics, vol. 37, no. 4, pp. 764–782, 2015.

E. I. Buchbinder and A. Desai, "CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition," American Journal of Clinical Oncology, vol. 39, no. 1, pp. 98–106, 2016.

E. M. Van Allen, D. Miao, B. Schilling et al., "Genomic correlates of response to CTLA-4 blockade in metastatic melanoma," Science, vol. 350, no. 6257, pp. 207–211, 2015.
[105] V. L. Chiou and M. Burotto, “Pseudoprogression and immune-related response in solid tumors,” Journal of Clinical Oncology, vol. 33, no. 31, pp. 3541–3543, 2015.

[106] P. Gotwals, S. Cameron, D. Cipollotta et al., “Prospects for combining targeted and conventional cancer therapy with immunotherapy,” Nature Reviews Cancer, vol. 17, no. 5, pp. 286–301, 2017.

[107] J. J. Luke, K. T. Flaherty, A. Ribas, and G. V. Long, “Targeted agents and immunotherapies: optimizing outcomes in melanoma,” Nature Reviews Clinical Oncology, vol. 14, no. 8, pp. 463–482, 2017.

[108] S. Rosner, E. Kwong, A. N. Shoushtari et al., “Peripheral blood clinical laboratory variables associated with outcomes following combination nivolumab and ipilimumab immunotherapy in melanoma,” Cancer Medicine, vol. 7, no. 3, pp. 690–697, 2018.

[109] J. Larkin, F. S. Hodi, and J. D. Wolchok, “Combined nivolumab and ipilimumab or monotherapy in untreated melanoma,” The New England Journal of Medicine, vol. 373, no. 13, pp. 1270–1271, 2015.

[110] L. Krähenbühl, S. M. Goldinger, J. Mangana et al., “A longitudinal analysis of IDO and PDL1 expression during immune- or targeted therapy in advanced melanoma,” Neoplasia, vol. 20, no. 2, pp. 218–225, 2018.

[111] L. Brochez, I. Chevolet, and V. Kruse, “The rationale of indoleamine 2,3-dioxygenase inhibition for cancer therapy,” European Journal of Cancer, vol. 76, pp. 167–182, 2017.

[112] I. Chevolet, R. Speckart, M. Haspeslagh et al., “Peritumoral indoleamine 2,3-dioxygenase expression in melanoma: an early marker of resistance to immune control?,” The British Journal of Dermatology, vol. 171, no. 5, pp. 987–995, 2014.

[113] S. Pasquali, A. V. Hadjimicouaou, V. Chiarion Sileni, C. R. Rossi, and S. Mocellin, “Systemic treatments for metastatic cutaneous melanoma,” Cochrane Database of Systematic Reviews, vol. 2, pp. 1–2, article CD011213, 2018.

[114] S. Na’ara, A. Mukherjee, S. Billan, and Z. Gil, “Contemporary multidisciplinary management of sinonasal mucosal Mela-noma,” OncoTargets and Therapy, vol. Volume 13, pp. 2289–2298, 2020.
A. D. Brumbaugh, R. Narurkar, K. Parikh, M. Fanucchi, and W. H. Frishman, “Cardiac immune-related adverse events in immune checkpoint inhibition therapy,” Cardiology in Review, vol. 27, no. 2, pp. 97–107, 2019.

J. M. Michot, J. Lazarovici, A. Tieu et al., “Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage?,” European Journal of Cancer, vol. 122, pp. 72–90, 2019.

E. Cha, M. Klinger, Y. Hou et al., “Improved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patients,” Science Translational Medicine, vol. 6, no. 238, article 238ra70, 2014.

L. Galluzzi, E. Vacchelli, J. M. B. S. Pedro et al., “Classification of current anticancer immunotherapies,” Oncotarget, vol. 5, no. 24, pp. 12472–12508, 2014.

D. Chowell, L. G. T. Morris, C. M. Grigg et al., “Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy,” Science, vol. 359, no. 6375, pp. 582–587, 2018.

M. Ayers, J. Lunceford, M. Nebozhyn et al., “IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade,” The Journal of Clinical Investigation, vol. 127, no. 8, pp. 2930–2940, 2015.

R. Salgado, C. Denkert, S. Demaria et al., “The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an international TILs working group 2014,” Annals of Oncology, vol. 26, no. 2, pp. 259–271, 2015.

N. R. West and F. Powrie, “Immunotherapy not working? Check Your Microbiota,” Cancer Cell, vol. 28, no. 6, pp. 687–689, 2015.

G. K. Alderton, “Intestinal bacteria are in command,” Nature Reviews Immunology, vol. 16, no. 1, p. 5, 2016.

A. Snyder, E. Pamer, and J. Wolchok, “IMMUNOTHERAPY. Could microbial therapy boost cancer immunotherapy?,” Science, vol. 350, no. 6264, pp. 1031-1032, 2015.

K. Dubin, M. K. Callahan, B. Ren et al., “Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis,” Nature Communications, vol. 7, no. 1, p. 10391, 2016.

N. Chaput, P. Lepage, C. Coutzac et al., “Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab,” Annals of Oncology, vol. 28, no. 6, pp. 1368–1379, 2017.

V. Gopalakrishnan, C. N. Spencer, L. Nezi et al., “Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients,” Science, vol. 359, no. 6371, pp. 97–103, 2018.

Y. Wang, D. H. Wiesnoski, B. A. Helmink et al., “Fecal microbiota transplantation for refractory immune checkpoint inhibitor- associated colitis,” Nature Medicine, vol. 24, no. 12, pp. 1804–1808, 2018.

A. E. Frankel, L. A. Coughlin, J. Kim et al., “Metagenomic shotgun sequencing and unbiased metabolomic profiling identify specific human gut microbiota and metabolites associated with immune checkpoint therapy efficacy in melanoma patients,” Neoplasia, vol. 19, no. 10, pp. 848–855, 2017.

A. Botticelli, I. Zizzari, F. Mazzuca et al., “Cross-talk between microbiota and immune fitness to steer and control response to anti PD-1/PDL-1 treatment,” Oncotarget, vol. 8, no. 5, pp. 8890–8899, 2017.